Haemonetics : Q4 2024 Analysis Tables & Supplemental Information

MANAGEMENT'S USE OF NON-GAAP MEASURES

The following tables contain financial measures that are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets, and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, Haemonetics Corporation's (the "Company's") reported financial results prepared in accordance with U.S. GAAP. In the following tables, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company's core operations and provide a baseline for analyzing trends in the Company's underlying businesses. We strongly encourage investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in the following tables, organic revenue growth excludes the impact of currency fluctuation and acquisitions. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.

						May 9, 2024
Reconciliation of Fiscal Year 2024 Net Revenues to the Revised Revenue Reporting Structure
In thousands
				Change
Q1 FY24		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	138,610	$	1,011	$	139,621
Apheresis		47,300		1,866		49,166
Whole Blood		20,040		-		20,040
Blood Center		67,340		1,866		69,206
Interventional Technologies(1)		37,620		-		37,620
Blood Management Technologies(2)		61,988		2,897		64,885
Hospital		99,608		2,897		102,505
Net business unit revenues		305,558		5,774		311,332
Service		5,774		(5,774)		-
Total net revenues	$	311,332	$	-	$	311,332
				Change
Q2 FY24		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	141,900	$	894	$	142,794
Apheresis		53,415		1,558		54,973
Whole Blood		14,683		-		14,683
Blood Center		68,098		1,558		69,656
Interventional Technologies(1)		38,541		-		38,541
Blood Management Technologies(2)		64,602		2,590		67,192
Hospital		103,143		2,590		105,733
Net business unit revenues		313,141		5,042		318,183
Service		5,042		(5,042)		-
Total net revenues	$	318,183	$	-	$	318,183
				Change
Q3 FY24		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	146,805	$	836	$	147,641
Apheresis		50,666		1,899		52,565
Whole Blood		19,814		-		19,814
Blood Center		70,480		1,899		72,379
Interventional Technologies(1)		43,007		-		43,007
Blood Management Technologies(2)		70,412		2,811		73,223
Hospital		113,419		2,811		116,230
Net business unit revenues		330,704		5,546		336,250
Service		5,546		(5,546)		-
Total net revenues	$	336,250	$	-	$	336,250
				Change
Q4 FY24		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	138,629	$	850	$	139,479
Apheresis		52,706		1,764		54,470
Whole Blood		17,520		-		17,520
Blood Center		70,226		1,764		71,990
Interventional Technologies(1)		55,116		-		55,116
Blood Management Technologies(2)		74,076		2,629		76,705
Hospital		129,192		2,629		131,821
Net business unit revenues		338,047		5,243		343,290
Service		5,243		(5,243)		-
Total net revenues	$	343,290	$	-	$	343,290
				Change
FY 2024		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	565,944	$	3,591	$	569,535
Apheresis		204,086		7,087		211,173
Whole Blood		72,058		-		72,058
Blood Center		276,144		7,087		283,231
Interventional Technologies(1)		174,285		-		174,285
Blood Management Technologies(2)		271,077		10,927		282,004
Hospital		445,362		10,927		456,289
Net business unit revenues		1,287,450		21,605		1,309,055
Service		21,605		(21,605)		-
Total net revenues	$	1,309,055	$	-	$	1,309,055

1. Interventional Technologies includes Vascular Closure and Sensor Guided Technologies product lines within the Hospital business unit.
2. Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines within the Hospital business unit.

						May 9, 2024
Reconciliation of Fiscal Year 2023 Net Revenues to the Revised Revenue Reporting Structure
In thousands
				Change
Q1 FY23		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	102,381	$	750	$	103,131
Apheresis		46,099		1,704		47,803
Whole Blood		19,595		-		19,595
Blood Center		65,694		1,704		67,398
Interventional Technologies(1)		29,568		-		29,568
Blood Management Technologies(2)		58,926		2,435		61,361
Hospital		88,494		2,435		90,929
Net business unit revenues		256,569		4,889		261,458
Service		4,889		(4,889)		-
Total net revenues	$	261,458	$	-	$	261,458
				Change
Q2 FY23		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	127,893	$	795	$	128,688
Apheresis		53,790		1,869		55,659
Whole Blood		19,893		-		19,893
Blood Center		73,683		1,869		75,552
Interventional Technologies(1)		29,575		-		29,575
Blood Management Technologies(2)		61,281		2,389		63,670
Hospital		90,856		2,389		93,245
Net business unit revenues		292,432		5,053		297,485
Service		5,053		(5,053)		-
Total net revenues	$	297,485	$	-	$	297,485
				Change
Q3 FY23		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	135,461	$	703	$	136,164
Apheresis		52,398		1,655		54,053
Whole Blood		20,964		-		20,964
Blood Center		73,362		1,655		75,017
Interventional Technologies(1)		32,154		-		32,154
Blood Management Technologies(2)		59,406		2,560		61,966
Hospital		91,560		2,560		94,120
Net business unit revenues		300,383		4,918		305,301
Service		4,918		(4,918)		-
Total net revenues	$	305,301	$	-	$	305,301
				Change
Q4 FY23		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	131,188	$	745	$	131,933
Apheresis		48,259		1,843		50,102
Whole Blood		18,964		-		18,964
Blood Center		67,223		1,843		69,066
Interventional Technologies(1)		35,420		-		35,420
Blood Management Technologies(2)		65,402		2,595		67,997
Hospital		100,822		2,595		103,417
Net business unit revenues		299,233		5,183		304,416
Service		5,183		(5,183)		-
Total net revenues	$	304,416	$	-	$	304,416
				Change
FY 2023		Previous		Allocation of		New
Revenues by Business Unit		Reporting	Service Revenue		Reporting
Plasma	$	496,923	$	2,993	$	499,916
Apheresis		200,546		7,072		207,618
Whole Blood		79,416		-		79,416
Blood Center		279,962		7,072		287,034
Interventional Technologies(1)		126,717		-		126,717
Blood Management Technologies(2)		245,014		9,979		254,993
Hospital		371,731		9,979		381,710
Net business unit revenues		1,148,616		20,044		1,168,660
Service		20,044		(20,044)		-
Total net revenues	$	1,168,660	$	-	$	1,168,660

1. Interventional Technologies includes Vascular Closure and Sensor Guided Technologies product lines within the Hospital business unit.
2. Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines within the Hospital business unit.

Revenue Growth by Business Unit under the Revised Revenue Reporting Structure

In thousands

					Reported	Currency	Acquisition	Organic
Revenues by Business Unit		Q1 FY24		Q1 FY23	Growth	Impact	Impact	Growth
Plasma	$	139,621	$	103,131	35.4%	(0.1)%	0.0%	35.5%
Apheresis		49,166		47,803	2.9%	(3.9)%	0.0%	6.8%
Whole Blood		20,040		19,595	2.3%	(1.6)%	0.0%	3.9%
Blood Center		69,206		67,398	2.7%	(3.3)%	0.0%	6.0%
Interventional Technologies(1)		37,620		29,568	27.2%	0.0%	0.0%	27.2%
Blood Management Technologies(2)		64,885		61,361	5.7%	(1.8)%	0.0%	7.5%
Hospital		102,505		90,929	12.7%	(1.3)%	0.0%	14.0%
Total net revenues	$	311,332	$	261,458	19.1%	(1.4)%	0.0%	20.5%
					Reported	Currency	Acquisition	Organic
Revenues by Business Unit		Q2 FY24		Q2 FY23	Growth	Impact	Impact	Growth
Plasma	$	142,794	$	128,688	11.0%	0.3%	0.0%	10.7%
Apheresis		54,973		55,659	(1.2)%	(3.0)%	0.0%	1.8%
Whole Blood		14,683		19,893	(26.2)%	(0.7)%	0.0%	(25.5)%
Blood Center		69,656		75,552	(7.8)%	(2.4)%	0.0%	(5.4)%
Interventional Technologies(1)		38,541		29,575	30.3%	(0.2)%	0.0%	30.5%
Blood Management Technologies(2)		67,192		63,670	5.5%	(0.5)%	0.0%	6.0%
Hospital		105,733		93,245	13.4%	(0.4)%	0.0%	13.8%
Total net revenues	$	318,183	$	297,485	7.0%	(0.6)%	0.0%	7.6%
					Reported	Currency	Acquisition	Organic
Revenues by Business Unit		Q3 FY24		Q3 FY23	Growth	Impact	Impact(3)	Growth
Plasma	$	147,641	$	136,164	8.4%	0.2%	0.0%	8.2%
Apheresis		52,565		54,053	(2.8)%	(1.9)%	0.0%	(0.9)%
Whole Blood		19,814		20,964	(5.5)%	0.1%	0.0%	(5.6)%
Blood Center		72,379		75,017	(3.5)%	(1.3)%	0.0%	(2.2)%
Interventional Technologies(1)		43,007		32,154	33.8%	(0.2)%	6.1%	27.9%
Blood Management Technologies(2)		73,223		61,966	18.2%	0.4%	0.0%	17.8%
Hospital		116,230		94,120	23.5%	0.2%	2.1%	21.2%
Total net revenues	$	336,250	$	305,301	10.1%	(0.2)%	0.6%	9.7%
					Reported	Currency	Acquisition	Organic
Revenues by Business Unit		Q4 FY24		Q4 FY23	Growth	Impact	Impact(3)	Growth
Plasma	$	139,479	$	131,933	5.7%	0.0%	0.0%	5.7%
Apheresis		54,470		50,102	8.7%	(3.5)%	0.0%	12.2%
Whole Blood		17,520		18,964	(7.6)%	(0.3)%	0.0%	(7.3)%
Blood Center		71,990		69,066	4.2%	(2.6)%	0.0%	6.8%
Interventional Technologies(1)		55,116		35,420	55.6%	(0.3)%	27.8%	28.1%
Blood Management Technologies(2)		76,705		67,997	12.8%	(0.3)%	0.0%	13.1%
Hospital		131,821		103,417	27.5%	(0.3)%	9.5%	18.3%
Total net revenues	$	343,290	$	304,416	12.8%	(0.7)%	3.3%	10.2%
					Reported	Currency	Acquisition	Organic
Revenues by Business Unit		FY 2024		FY 2023	Growth	Impact	Impact(3)	Growth
Plasma	$	569,535	$	499,916	13.9%	0.1%	0.0%	13.8%
Apheresis		211,173		207,618	1.7%	(3.0)%	0.0%	4.7%
Whole Blood		72,058		79,416	(9.3)%	(0.6)%	0.0%	(8.7)%
Blood Center		283,231		287,034	(1.3)%	(2.3)%	0.0%	1.0%
Interventional Technologies(1)		174,285		126,717	37.5%	(0.2)%	9.3%	28.4%
Blood Management Technologies(2)		282,004		254,993	10.6%	(0.6)%	0.0%	11.2%
Hospital		456,289		381,710	19.5%	(0.5)%	3.1%	16.9%
Total net revenues	$	1,309,055	$	1,168,660	12.0%	(0.7)%	1.0%	11.7%

1. Interventional Technologies includes Vascular Closure and Sensor Guided Technologies product lines within the Hospital business unit.
2. Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines within the Hospital business unit.
3. Reflects the impact in Hospital of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023.